Literature DB >> 32655145

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.

Jennifer R Brown1, Andrew Zelenetz2, Richard Furman3, Nicole Lamanna4, Anthony Mato5, Marco Montillo6, Susan O'Brien7, Ronald Dubowy8, Lin Gu8, Veerendra Munugalavadla8, Tadeusz Robak9, Peter Hillmen10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32655145      PMCID： PMC7829041          DOI： 10.1038/s41375-020-0974-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.

Authors:  Deepti Gadi; Alec Griffith; Zixu Wang; Svitlana Tyekucheva; Vanessa Rai; Stacey M Fernandes; John-Hanson Machado; Veerendra Munugalavadla; James Lederer; Jennifer R Brown
Journal:  Br J Haematol       Date:  2022-02-15       Impact factor: 8.615

Review 2.  The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-27       Impact factor: 2.861
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.